- Home
- ACCD vs PEPG Comparison
ACCD vs PEPG Comparison
Compare ACCD & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACCD
- PEPG
- Stock Information
- Founded
- ACCD 2007
- PEPG 2018
- Country
- ACCD United States
- PEPG United States
- Employees
- ACCD N/A
- PEPG N/A
- Industry
- ACCD Business Services
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- ACCD Consumer Discretionary
- PEPG Health Care
- Exchange
- ACCD Nasdaq
- PEPG Nasdaq
- Market Cap
- ACCD 281.1M
- PEPG 250.3M
- IPO Year
- ACCD 2020
- PEPG 2022
- Fundamental
- Price
- ACCD $3.70
- PEPG $4.41
- Analyst Decision
- ACCD Buy
- PEPG Buy
- Analyst Count
- ACCD 12
- PEPG 3
- Target Price
- ACCD $9.04
- PEPG $14.67
- AVG Volume (30 Days)
- ACCD 1.3M
- PEPG 137.0K
- Earning Date
- ACCD 01-06-2025
- PEPG 11-07-2024
- Dividend Yield
- ACCD N/A
- PEPG N/A
- EPS Growth
- ACCD N/A
- PEPG N/A
- EPS
- ACCD N/A
- PEPG N/A
- Revenue
- ACCD $441,028,000.00
- PEPG N/A
- Revenue This Year
- ACCD $15.56
- PEPG N/A
- Revenue Next Year
- ACCD $11.76
- PEPG N/A
- P/E Ratio
- ACCD N/A
- PEPG N/A
- Revenue Growth
- ACCD 16.04
- PEPG N/A
- 52 Week Low
- ACCD $3.08
- PEPG $4.00
- 52 Week High
- ACCD $15.36
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- ACCD 57.22
- PEPG 25.54
- Support Level
- ACCD $3.30
- PEPG $4.00
- Resistance Level
- ACCD $3.80
- PEPG $4.77
- Average True Range (ATR)
- ACCD 0.18
- PEPG 0.55
- MACD
- ACCD 0.04
- PEPG -0.01
- Stochastic Oscillator
- ACCD 87.14
- PEPG 11.71
About ACCD Accolade Inc.
Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.